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Summary
Objectives: To review the seven Cochrane reviews of non-antibiotic treatment for
the common cold.
Methods: Each Cochrane review was read and summarized, and results presented as
relative risks and, where possible, numbers needed to treat.
Results: The main theme that runs through these Cochrane reviews is the variable
quality of the primary studies. In general, the reviewers are fairly cautious about the
benefits of any of the treatments other than first-dose decongestants and
antihistamine–decongestant combinations. For antihistamines alone, the reviewers
were clear about the lack of efficacy except in the high-quality studies in which a
global improvement in symptoms was noted. Some studies were statisticallyee front matter & 2005
med.2005.09.039
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ess: b.arroll@auckland.significant, but the Cochrane reviewers were guarded about how clinically significant
they were. For Echinacea, problems were found with the quality of the studies and
the wide range of different forms of this substance. Heated humidified air seemed to
be effective in the UK and Israel, but not the USA, making definitive statements
about efficacy difficult. Over-the-counter medication for cough seemed to have no
documented benefit in children under the age of 5 years. Letosteine (a mucolytic)
may be effective in children but is not available in the UK. Bisolvon (a mucolytic) was
found to be effective for cough in only one study. For older children and adults,
dextromethorphan may be effective (two out of three studies showed benefit), and
guiafenesin (an expectorant) showed mixed benefit in two trials. Dexbromphenir-
amine (a sedating antihistamine)/pseudoephedrine (6mg/120mg twice daily for 1
week) was significantly more effective than placebo for severity of cough, whereas,
in another study, loratadine (a non-sedating antihistamine)/pseudoephedrine (5mg/
120mg twice daily for 4 days) did not show any difference between the study groups.
Vitamin C may have a small role in preventing the common cold, with possibly a
greater role in high-intensity physical activity and sub-arctic conditions. ZincPublished by Elsevier Ltd.
rane reviews cited in this evidence-based review.
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B. Arroll1478lozenges seemed to be effective, but the issue of unblinding due to taste was a
methodological issue of concern to the reviewers. The benefits and harms are
calculated as numbers needed to treat for one person to benefit (NNTB) and numbers
needed to treat for one person to harm (NNTH), and were calculated by the author.
Conclusion: Most non-antibiotic treatments for the common cold are probably not
effective. The most promising are dextromethorphan, bisolvon and guiaphenesin for
cough, antihistamine–decongestant combinations for a wide range of symptoms,
nasal decongestants (at least for the first dose) and possibly zinc lozenges.
& 2005 Published by Elsevier Ltd.Introduction
This paper evaluates the seven Cochrane systema-
tic reviews that deal with non-antibiotic treat-
ments for upper-respiratory tract infection. This
was originally intended to include the review of
anti-viral treatment for the common cold, but this
review has been removed from the library as it was
not updated. The treatments in this review are
those that may be self-administered in many
jurisdictions (e.g. heated humidified air), as well
as being recommended in others by clinicians and
even subsidized by some health funders. Thus, the
term ‘‘over-the-counter’’ (OTC) is not strictly
correct. Most of the clinical syndromes in this
review fit the definition of the common cold, but,
as mentioned in the earlier review in this series on
‘‘antibiotics for upper-respiratory tract infections:
a review of Cochrane reviews,1’’ there is the issue
of microbiological aetiology to consider. It is not
always clear if an infection is of a viral, bacterial or
mixed nature. In this paper, infections are assumed
to be mainly viral, but the microbiology is not
usually known or sought by clinicians.
In this overview, effects may be reported as the
NNTB (number needed to treat for one person to
benefit) and the NNTH (number needed to treat for
one person to harm). The NNTB is the inverse of the
absolute risk reduction (ARR) resulting from a
particular treatment in a particular group of
patients.2 It is felt that it is better to report the
ARR than the relative risk reduction, as this term
refers to the benefit of a treatment without any
reference to the baseline risk. Both the ARR and
the NNTB (the reciprocal of ARR) take these factors
into consideration. The same applies to the NNTH
for harm. The NNTB and the NNTH were only
reported in this review if they were from statisti-
cally significant studies or statistically significant
pooled relative risks. The latter is calculated
by obtaining a pooled relative risk from the
meta-analysis and applying it to the patient
expected event rate (PEER). The PEER is the rate
of events that occur in the group taking the placebomedication in a randomized trial comparing drug
with placebo. Therefore, if the relative risk is less
than 1 then the NNTB ¼ 1/{(1RR) PEER}, and if
the relative risk is greater than 1 then the
NNTB ¼ 1/{(RR1) PEER}.2
A number of issues affect the quality of the
reviews covered in this paper. These include a wide
range of design quality in the studies reviewed. The
dose and quality of some of the medicinal compo-
nents and combination medications are also issues
of concern. The latter two of these apply particu-
larly to OTC medications. Issues are also raised by
different methods of measuring end points, such as
continuous scales compared with dichotomous out-
comes (i.e. feeling well or absence of cough). As
some of the medications are designed for specific
purposes (e.g. cough suppressant), then absence of
cough will be appropriate. For decongestants, it
will be nasal discharge and stuffiness. This raises
the question of what would be the appropriate
outcome for an antihistamine for the common cold.
Ideally, the primary outcomes are specified
beforehand. However, it is not always possible to
tell if the analysis was done on the outcomes of
primary interest or on the secondary outcomes. In
this particular field, underpowering because of
small study size is also an issue. NNTB can only be
calculated if dichotomous outcomes are used, but
they can be calculated for different symptoms,
providing some practical information to guide
treatment decisions.Antihistamines for the common cold
The systematic review on antihistamines for the
common cold3 was undertaken because the use of
antihistamines for the common cold is widespread
yet there was concern that they may not be
effective. The review contained 32 papers with 35
comparisons; 22 trials were of monotherapy and 13
were of a combination of antihistamines with other
medication. The number of participants totalled
8930. The authors reported large differences in
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comes. For monotherapy, no evidence was found of
a clinically significant effect on general recovery
with antihistamines as monotherapy for either
children or adults.
A benefit for global improvement was found in a
subgroup analysis of the higher quality studies of
first-generation sedating antihistamines. The rela-
tive risk (RR) for benefit was 0.9; 95% confidence
interval (CI) 0.82–0.98. On the basis of the range of
PEERs in individual studies in this review, the NNTB
for a benefit was 12 for a PEER of 0.81 (this means
that 81% of patients still had symptoms at the time
of analysis) and 17 for a PEER of 0.6. The RR for
adverse effects for the sedating antihistamine was
1.20 (95% CI 1.03–1.40). The NNTH for a PEER of
0.05 was 93 and for 0.36 the NNTH was 14. For the
non-sedating antihistamines, no sedating adverse
effects were found (RR ¼ 1.10; 95% CI 0.55–2.18).
For monotherapy in small children aged 2–5 years,
there was little evidence of benefit. One large trial
(6 months to 5 years) found no benefit, and one
smaller trial found improved rhinorrhea.
Combination antihistamine–decongestant
Similar lack of benefit was seen with combination
of antihistamines and decongestants for young
children. In older children and adults, evidence of
benefit was found, and this was seen in five out of
the six included trials. The RR for benefit in terms
of global evaluation at 2–4 days was 0.31 (95% CI
0.15–0.65). This is an NNTB of 2.5 for a PEER of 0.58
and an NNTB of 4 for a PEER rate of 0.39. For the
only significant harm (dry mouth), the RR was 1.93
(95% CI 1.35–2.75). The NNTH ranged from 2–46 for
the PEER rates of 0.023 and 0.54, respectively. This
suggests that more patients may experience an
adverse event (dry mouth) than will benefit from
combination antihistamines and decongestants.
The following interpretation can be made on the
basis that (1) combination therapies seem to be
effective; (2) monotherapy with antihistamines is
not effective; and (3) the systematic review on
decongestants (below)4 shows some benefit: it may
be the decongestant component of the combination
medications that is providing the effectiveness, and
the antihistamine is contributing little or nothing to
efficacy.Echinacea
The systematic review on Echinacea5 included 16
studies (eight were of prevention and eight oftreatment for upper-respiratory tract infections),
with a total of 3396 participants. There was such
variation in the preparations used and the quality
of the study methods, that the authors felt that
they could not pool the results.
Prevention in placebo trials
Two of the five prevention trials with a placebo
found a statistically significant lower incidence of
infection in the treatment group (RR ¼ 0.51 and
0.67), whereas, in the other trials, there were only
trends in favour of the treatment groups. The
pooled RR was 0.86 (95% CI 0.72–1.02). In assessing
the severity and duration of infections, three trials
found no clear trends favouring the treatment or
the placebo group in the severity of recurring
infections.
Prevention trials with no placebo
In all three prevention trials with no treatment
controls, the number of children with infection
was significantly lower in the group receiving
the Echinacea combination compared with the
no treatment group. The pooled RR for these
studies was 0.56 (95% CI 0.48–0.65). The concern
with these trials is that there was no placebo, so
caution is needed in interpreting this ‘‘positive’’
result.
Treatment versus placebo
In the six trials comparing treatment with placebo,
the outcomes (symptom scores, running nose and
duration of illness) was a statistically significant
pooled result. They were continuous outcomes, and
hence an NNTB could not be calculated. In the four
trials of treatment comparing placebo with running
nose as the outcome, the pooled result was
statistically significant (weighted mean difference
[WMD] 0.65; 95% CI 0.93 to 0.37). In two trials
comparing treatment with placebo for outcomes in
terms of duration of symptoms, the pooled result
was statistically significant (WMD 1.0; 95% CI
1.98 to 0.02). In a recent, large, placebo-
controlled trial, Echinacea purpurea, as dosed in
this study, was not effective in treating upper-
respiratory infection symptoms in children aged
between 2 and 11 years, and its use was associated
with an increased risk of rash.6 The authors of the
Cochrane review made the following comments:
‘‘While overall there is some positive evidence, few
recommendations can be made regarding the use of
Echinacea products in practice. The heterogeneity
ARTICLE IN PRESS
B. Arroll1480of the available preparations and the limited
quality and consistency of the evidence do not
allow clear conclusions about which product might
be effective in what dose and in what circum-
stances. Patients and healthcare providers who
want to use preparations containing extracts of
Echinacea should be aware of the possible extreme
differences in the chemical composition and that
there is no solid base of evidence concerning their
efficacy.5’’Heated, humidified air for the common
cold
This systematic review on heated, humidified air
for the common cold7 assessed the use of inhaled
heated water vapour with the help of a rhinotherm
(a machine designed to deliver heated water
vapour to a person’s nasal cavity) in the treatment
of the common cold. The control group usually
received unheated humidified air. Efficacy of this
intervention in the studies carried out in UK and
Israel differed from those carried out in the USA
with similar equipment and methodology. The
studies from Israel and UK reported beneficial
effect of rhinothermy in individuals with rhinophar-
yngitis, whereas three randomized-controlled trials
from the USA failed to replicate the findings of
these previous investigators. Equipment used to
administer the warm vapour differed slightly in the
UK (anaesthetic mask) and USA (nozzle). Findings
for symptom score, nasal culture washings or a
subjective perception of benefit were not signifi-
cant. The reviewers concluded by stating: ‘‘since
the studies reporting use of rhinothermy have
shown only subjective benefit in the symptoms of
the common cold in the UK and Israel, this therapy
cannot be recommended universally because the
results of trials from the US are equivocal.’’Nasal decongestants for the common
cold
Five studies were suitable for inclusion in the
review on nasal decongestants for the common
cold,4 which contained only single component or
single-dose studies. For the single-dose studies,
four studies were included, and all were statisti-
cally significant for a reduction in the nasal
symptom of congestion after treatment compared
with placebo. The WMD between active and
placebo was 0.13 (95% CI 0.19 to 0.06).
Discrete outcomes were not reported, hence anNNTB was not able to be calculated. No objective
data were available for these studies. Overall, the
reduction in nasal airway resistance for active
medication compared with placebo was significant.
The forms of medication included oxymetazoline
nasal drops, oral phenylpropranolamine, oral nor-
phedrine and oral pseudoephedrine.
For the multiple-dose studies, only one study
used oral psuedoephedrine 60mg.8 No significant
benefit was found for the symptom of congestion
after repeated doses of decongestant over a 5-day
period. Again, no discrete data were reported,
hence NNTB could not be calculated. Because of
the lack of other studies to support this result, no
conclusion can be drawn on the efficacy of
repeated doses of decongestant.Over-the-counter medications for acute
cough in children and adults in
ambulatory settings
Acute cough is a common symptom, and is often
associated with the common cold. Many people
self-prescribe OTC cough medicines for themselves
or their children, and many primary-care clinicians
recommend them to their patients as first-line
treatment. OTCs are available to the public from
pharmacies and shops often without medical pre-
scription, although, in some countries, they can be
prescribed (Table 1).
Antitussives in adults
The Cochrane review of OTC medications for acute
cough in children and adults in ambulatory settings9
assessed six trials comparing antitussives with
placebo. Codeine was no more effective than
placebo in reducing cough symptoms in doses of
120mg per day or as a single dose of 50mg. Three
studies were included, all of which examined
dextromethorphan in a single dose of 30mg. Two
studies favoured dextromethorphan over placebo,
whereas a third study showed no effect. Moguis-
teine in doses of 600mg/day was no more effective
than placebo, apart from reducing cough in a
subgroup of participants with more severe night
cough. Significant adverse effects were found in
the intervention group, which consisted mainly of
nausea, vomiting and abdominal pain (NNTH ¼ 7).
Expectorants in adults
Two trials compared guaifenesin with placebo. In
the larger study, participants taking guaifenesin
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was helpful compared with placebo in reducing the
cough frequency and intensity, with an NNTB of 2.
Four participants (two in each group) reported
side-effects, including nausea and hives in the
active treatment group, and headaches, drowsiness
and excessive perspiration in the placebo group. In
another study, sputum thickness was significantly
reduced for guaifenesin 480mg 6 hourly with an
NNTB of 2. Adverse effects were not reported in
this study.
Mucolytics in adults
One trial compared a mucolytic (bisolvon linctus)
5mg three times daily for an average of 4 days with
placebo. Active treatment reduced cough fre-
quency and symptom scores on days 4 and 8. The
NNTB was 15 and adverse effects were not
reported.
Antihistamine–decongestant combinations in
adults
Two studies compared antihistamine–decongestant
combinations with placebo. Dexbrompheniramine
(a sedating antihistamine)–pseudoephedrine (6mg/
120mg twice daily for 1 week) was significantly
more effective than placebo for severity of cough.
Adverse effects increased, including dizziness and
dry mouth. In the other study, loratadine (a non-
sedating antihistamine)–pseudoephedrine (5mg/
120mg twice daily for 4 days) did not show any
difference between the study groups. Thirty per
cent of the intervention reported dry mouth,
headache and insomnia compared with 21% in the
placebo group. This translated to an NNTH of 11.Table 1 Potential treatments for the common cold.
Type Symptom NNTB
Antihistamine Global improvement 12–17
Antihistamine
decongestant
General improvement
and nasal symptoms
2.5–4
Dextromethorphan Cough NR
Nasal decongestant Congestion NR
Guaifenesin Cough, sputum
thickness
2
Bisolvon Cough 15
Zinc lozenges Symptoms of cold 4–8
Some of these results differ from the conclusions of specific Co
give some direction to patients keen on taking a remedy. NNTB
number needed to treat for one person to harm; NR, not reporteOther drug combinations in adults
Three studies compared combinations of drugs
other than antihistamine–decongestant with place-
bo. They contained multiple compounds, such as
Vicks Mednite, which contains dextromethorphan,
doxylamine, ephedrine and paracetamol. When
Vicks Mednite was given as a single dose at bedtime
for 2 days, 57.6% of participants in the active
treatment group rated the formulation as ‘‘good’’
or better in relieving cough compared with 32.2% in
the placebo group, with an NNTB of 4. Seven
participants in the active treatment group reported
giddiness or drowsiness compared with four parti-
cipants in the placebo group. Another medica-
tion known as EM-VIER was more effective than
placebo for reducing cough in adults (reduced
coughing fits 25% vs. 11%, NNTB 7 and reduced
urge to cough with NNTB of 7). No adverse effects
were observed in both groups. Another study
compared a dextromethorphan–salbutamol combi-
nation, and dextromethorphan alone with placebo.
Dextromethorphan–salbutamol was superior to pla-
cebo or dextromethorphan alone in relieving cough
at night (mean symptom score 0.19 vs. 0.67 and
0.44, respectively, on day 4. The dextromethor-
phan–salbutamol combination led to more tremor
than placebo, and no serious adverse effects were
reported.
Antihistamines in adults
Three trials compared antihistamines with placebo.
Antihistamines were no more effective than place-
bo in relieving cough symptoms. Adverse events
were about equal in the intervention and control
groups.NNTH Cochrane reviewers’ assessment
14–93 Only for high-quality studies
11 Dry mouth. Not effective in under
5-year olds
NR Two out of three studies show
benefit
NR Benefit only at 1 day
NR Both studies had significant results
NR Only one study on this medication
6 Concerns about unblinding
chrane reviews, but are presented in a comparative format to
, number needed to treat for one person to benefit; NNTH,
d.
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Antitussives in children
One study of 57 children (mean age 4.7 years; range
18 months to 12 years) with night cough compared
a single dose for 3 nights of dextromethorphan and
codeine with placebo. No benefit was found for
either medication over placebo.Expectorants in children
No studies using expectorants met the reviewers’
inclusion criteria.Mucolytics in children
A trial of letosteine (25mg three times daily for 10
days with placebo) reported symptom score on a
four-point scale favouring active treatment from
day 4 until day 10. This medication is not currently
available in the UK.Antihistamine–decongestant combinations
Two studies compared antihistamine–decongestant
(brompheniramine–phenylpropanolamine) combi-
nations in children aged 6 months to 5 years, and
neither was more effective than placebo. In one of
the studies, a higher proportion of children were
asleep in the active treatment group (46.6%) than
in the placebo group (26.5%, P ¼ 0:53).Other drug combinations
One trial involving 43 children tested two paedia-
tric cough syrups (Triaminicol syrup and Dorcol
paediatric cough syrup). Compared with placebo,
69% of children in both active treatment groups
showed a satisfactory response reported by their
parents compared with 57% of children in the
placebo group, which did not reach statistical
significance (P ¼ 0:5). Adverse effects were not
reported.
Another RCT in 51 children compared a combina-
tion of dextromethorphan 1.5mg per ml and
salbutamol 0.2mg per ml 5ml three times daily
for children under the age of 7 years or 10ml three
times a day for older children with placebo. There
was no evidence of efficacy.Antihistamines in children
One trial testing antihistamines in children aged
1.5–5 years found that they were no more effective
than placebo.Vitamin C
The role of oral vitamin C (ascorbic acid) in
preventing and treating the common cold has been
controversial for many years. Public interest is
high, and vitamin C continues to be widely sold and
used as a preventive and therapeutic agent for this
condition. The systematic review on vitamin C10
only considered studies of vitamin C 200mg or more
per day.Prevention of the common cold
Twenty-three studies in ‘‘normal people’’ were
included, and the pooled relative risk was
of borderline statistical significance (RR 0.98;
95% CI 0.95–1.00). A subgroup of six papers study-
ing marathon runners, skiers and soldiers on sub-
arctic exercises reported another pooled relative
risk of borderline statistical significance for pre-
vention of common colds (RR 0.96; (95% CI
0.92–1.00).
The Cochrane reviewers make this comment:
‘‘Although these findings point to a definite
physiological effect by prophylactic vitamin C on
common cold duration, the practical significance of
these findings is less convincing. It would not seem
reasonable to ingest vitamin C regularly in the
mega-dose range throughout the year if the only
anticipated benefit is to rather slightly shorten the
duration of colds which occur for adults, two or
three times per year. Our pooled estimate suggests
that long-term supplementation might result in an
upper estimate average reduction of annual com-
mon cold morbidity from about 12 days (based on
Douglas 1979; unpublished Australian data) to
about 11 days per year for adults. For children
under 12 years who experience colds more fre-
quently, long-term prophylaxis might be associated
with an average reduction in 4 symptom days from
about 28 days to 24 days per year per child. Such a
benefit is not trivial, but is it worth the cost of long-
term prophylaxis, and could an equivalent benefit
perhaps be achieved in children through therapy
alone?’’ They also make the comment that, in some
populations, there may be a low intake of vitamin C
and hence explain why some studies find a benefit
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account regular vitamin C intake.Treatment of the common cold with
vitamin C
Seven trials of treatment of the common cold after
symptoms have been published, but no significant
difference was seen from placebo. However, one
large trial reported equivocal benefit from a 4 g
therapeutic dose at onset of symptoms.Prevention of the common cold with
vitamin C
The failure of vitamin C supplementation to reduce
the incidence of colds in the normal population
indicates that routine mega-dose prophylaxis is not
rationally justified for community use. However,
evidence shows that it could be justified in people
exposed to brief periods of severe physical ex-
ercise, cold environments, or both. Also, the
consistent and statistically significant small bene-
fits on duration and severity for people using
regular vitamin C prophylaxis indicates that vitamin
C plays some role in respiratory defence mechan-
isms.Zinc for the treatment of the common cold
The systematic review of zinc for the treatment of
the common cold11 included seven studies examin-
ing the use of zinc lozenges for the treatment of
the common cold. The reviewers were conservative
about the findings, yet an intention-to-treat analy-
sis at 7 days found a statistically significant RR of
0.69 (95% CI 0.56–0.85). The NNTB ranged from 4 to
8 for PEERs at 0.62 to 0.34, respectively. The authors
were concerned about the dose of medication and
blinding of studies. In four trials, participants
treated with zinc complained of altered or bad or
unpalatable taste, which suggests zinc lozenges
were distinct from placebo lozenges and, in this
respect, blinding may have been compromised.
In one of the trials, the formulation contained
13.3mg zinc, about half that used in most other
trials; the incidence of nausea in participants
treated with zinc (10/49) was significantly in-
creased from that reported for participants taking
placebo (2/50). This is an NNTH of 6. Irritation of
the oral mucosa and distortion of taste have also
occurred at higher incidences in participants
treated with zinc.Practice points
 Negotiation about the likely benefits and
harms of any of the non-antibiotic treat-
ments is warranted, as few are consistently
beneficial.
 First-dose decongestants, either topical or
oral, seem to be effective for symptom
control
 Antihistamine decongestant combinations
seem to be effective for a wide range of
symptoms
 Patients need to be reminded that symp-
toms do linger and that, at 10 days from the
onset of illness with the common cold, 25%
still have symptoms12Research directions
 A large, high-quality factorial, randomized-
controlled trial comparing antihistamines,
decongestants and the combination with
placebo needs to be undertaken to clarify
the effective component(s)
 Large, high-quality, randomized-controlled
trials are needed to clarify the efficacy of
dextromethorphan, bisolvon and guiafenesinReferences
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